key: cord-1028400-w50xc1l3
authors: K., Deepthi; A.S., Jereesh; Liu, Yuansheng
title: A deep learning ensemble approach to prioritize candidate drugs against novel coronavirus 2019-nCoV/SARS-CoV-2
date: 2021-10-06
journal: Appl Soft Comput
DOI: 10.1016/j.asoc.2021.107945
sha: 8f492360d051435304503bdb0acae26a197c8ace
doc_id: 1028400
cord_uid: w50xc1l3

The alarming pandemic situation of Coronavirus infectious disease COVID-19, caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has become a critical threat to public health. The unexpected outbreak and unrealistic progression of COVID-19 havegenerated an utmost need torealize promising therapeutic strategiesto fight the pandemic. Drug repurposing-an efficientdrug discovery technique from approved drugs is an emerging tacticto face the immediate global challenge.It offers a time-efficient and cost-effective way to find potential therapeutic agents for the disease. Artificial Intelligence-empowered deep learning models enable the rapid identification of potentially repurposable drug candidates against diseases. This study presents a deep learning ensemble model to prioritize clinically validated anti-viral drugs for their potential efficacy against SARS-CoV-2. The method integrates the similarities of drug chemical structures and virus genome sequences to generate feature vectors. The best combination of features is retrieved by the convolutional neural network in a deep learning manner. The extracted deep features are classified by the extreme gradient boosting classifier to infer potential virus-drug associations. The method could achieve an AUC of 0.8897 with 0.8571 prediction accuracy and 0.8394 sensitivity under the fivefold cross-validation. The experimental results and case studies demonstrate the suggested deep learning ensemble system yields competitive results compared with the state-of-the-art approaches. The top-ranked drugs are released for further wet-lab researches.

integrate the potential of multiple classifiers, thus yield models with enhanced predictive power and credibility. The proposed approach combines the pairwise similarities of drug chemical structures and virus genome sequences to build classification features. The generated samples were fed to the convolutional neural network for learning intricate input patterns. The learned abstract features were used to train the extreme gradient boosting classifier, which infers promising candidate drugs against SARS-CoV-2 infections. We The rest of the paper is organized as follows: Section 2 discusses a review of recent works in drug repositioning to identify potential therapeutic drugs targeting covid-19. Section 3 describes the data preparation and architectural details of DLEVDA. Section 4 presents and analyzes the results of the proposed method.

Section 5 discusses the results and Section 6 concludes the paper with future directions.

Based on the method, computational DR applied to infer anti-viral drugs against COVID-19 falls mainly into two categories: network-based and machine learning-based. Network-based DR methods represent drugs, diseases, and other biological entities like proteins, genes, etc., as network nodes and their associations as edges between nodes. Zhou et al. [14] suggested a method that identifies new anti-viral drugs against covid-19 by analyzing the association networks related to the Human coronaviruses (HCoVs) and drugs with their target proteins in the human protein-protein interaction (PPI) network. They collected the target proteins related to the HCoVs and generated the HCoV-host protein subnetwork. By computing the network proximity among the drug's target proteins and HCoV-related proteins, potential anti-SARS-CoV-2 drugs were identified. Fiscon et al. [15] proposed a method that identifies new anti-viral drugs against covid-19 from already approved drugs.

They quantified the relationships between drug targets and disease-associated genes using a network similaritybased approach to identify repurposable anti-SARS-CoV-2 drugs. The method utilized a drug-target network based on the drugs and their target proteins and a disease-gene network based on the diseases and their associated genes for prediction. The idea behind the algorithm is that a drug will be effective for a specific J o u r n a l P r e -p r o o f disease if the drug targets and the disease genes are nearby in the constructed network. Their algorithm calculated the network proximity value between each drug and disease to prioritize appropriate drug candidates against SARS-CoV-2. Meng et al. [16] proposed a method that predicts new anti-viral drugs against SARS-CoV-2 using similarity constrained probabilistic matrix factorization. They utilized drug chemical structure and virus genomic sequence-based similarities and known drug-virus relationships for prediction. They applied probabilistic matrix factorization on the drug-virus relationship matrix by introducing similarity constraints for drugs and viruses in the factorization process.

Adhami et al. [17] suggested a method that infers novel therapeutic drugs against COVID-19 by identifying the causal genes behind it. They retrieved the PPI network corresponding to the human proteins interacting with SARS-CoV-2 from the String database [18] . They identified 7 clusters of proteins that are deeply linked to SARS-CoV-2 and retrieved the genes and associated miRNAs related to the identified protein clusters. Finally, they acquired the drug targeting gene modules from the DGIdb [19] and then rebuilt the druggene network for the obtained protein modules. Next, they implemented a network-oriented drug repositioning method using computational bioinformatics tools to identify novel anti-viral drugs to fight COIVD-19. Peng et al. [20] presented an approach that predicts novel anti-viral drugs against COVID from FDA-approved drugs by utilizing drug chemical structure similarities, virus genome sequence-based similarities, and known drug-virus relationships. By integrating this data, they built a heterogeneous network and applied the random walk with restart algorithm [21] on the built network to identify new anti-viral drugs against SARS-CoV-2. The algorithm predicts the association score between SARS-CoV-2 and each drug in the dataset.

Though artificial intelligence-based researches are very active in tackling the Covid-19 epidemic, few articles are concerned with DR. Beck et al. [22] suggested a method that identifies currently available drugs that can interact with the proteins of SARS-CoV-2. They trained a pre-trained drug-target interaction prediction deep learning model [23] , with the samples made of drug SMILES (Simplified Molecular Input Line Entry System) strings and amino acid sequences to infer new drug-virus associations. Ke et al. [24] implemented a deep learning method that prioritizes known drugs for their efficacy in fighting against SARS-CoV-2. They trained the model with two datasets; one with the approved drugs against viruses like SARS-CoV, influenza virus, etc., and the other with the confirmed protease inhibitors. They tested the efficacy of the identified drugs using in vitro cell-based assays. With the obtained results, they retrained their model and finally built a model that could identify efficacious drugs against COVID-19. Both of these studies did not evaluate their models quantitatively, and so they do not have exactly comparable results. Systematic deep learning or ensemble machine learning techniques are not applied in the field of virus-drug association prediction. Based on the status of the studies mentioned above, we are proposing a deep learning ensemble approach to infer novel virus-drug associations for identifying promising drug candidates against SARS-CoV-2. Intra-drug similarities: The intra-drug similarities were quantified based on the chemical structures of drugs.

The drug chemical structures were acquired from DrugBank [25] by adopting the SMILES format [26] . The Molecular Access System (MACCS) fingerprints of drugs were computed using Open Babel v2.3.1 [27] . The similarity between the two drugs was measured using the Tanimoto index [28] based on their MACCS fingerprints. The Tanimoto index between two drugs can be defined as:

where and represent the number of bits set in the corresponding drug fingerprints, and represents the number of bits that are set in both the fingerprints.

The intra-virus similarities were measured based on the virus genome sequences. The virus genome nucleotide sequences belonging to the human hosts were acquired from National Center for Biotechnology Information, NCBI [29] . Their pairwise sequence similarities were computed with Multiple Alignment using Fast Fourier Transform, MAFFT version 7 [30] , a multiple sequence alignment tool.

The known drug-virus relationships and the pairwise similarities among drugs and viruses were acquired from [16] ; We consider it the benchmark dataset for this study.

In this research, we presented an ensemble machine learning method that identifies new virus-drug relationships 

CNN is a deep learning algorithm proposed by Lecun et al. [31] that consists of three essential layersconvolutional layer, subsampling layer, and fully connected layer. Convolutional layers are the primary building blocks of CNN which are capable of capturing hidden patterns from the raw input data. CNN comprises two fundamental sections: feature extraction and classification. Feature extraction is achieved by multiple convolutions and subsampling layers and classification by fully connected layers. CNNs were effectively utilized for feature learning and classification in prediction problems for identifying the relationships between diseases, drugs, microRNAs, circular RNAs, etc. [32] [33] [34] . In DLEVDA, we employed CNN for extracting the sophisticated input patterns from the concatenated drug-virus feature vectors in a deep learning manner. We performed multiple convolution operations on the input samples using different kernels to generate the activation map. The activation map at layer can be described as:

where ( ) denotes the activation function, the convolution kernel at layer k, the offset vector, and ⊙ the convolution operation. To compress data and minimize overfitting, the subsampling layer is used. The sampling formula at the subsampling layer can be expressed as:

We employed max-pooling at the subsampling layer, which retains the most prominent feature at each filter area. The CNN was trained to decrease the loss function of the network. The training samples were sent to the CNN to capture the significant features. To get our best model, we tuned the CNN hyper-parameters through several experiments. We implemented the convolution operation by using 16 filters of 1×16 size. At the subsampling layer, we set the filter size to 1×2. We used rectified linear unit, Relu [35] , as the activation function at the convolution and fully connected layers and the sigmoid function at the output layer. The model was implemented using binary cross-entropy as the error function and Adam as the optimizer. To prevent overfitting, dropout layers [36] are added with convolution and hidden layers. Finally, the learned latent representations after numerous convolution and pooling operations are retrieved for identifying the potential virus-drug relationships.

XGBoost is a classification algorithm founded by Chen and Guestrin [37] which works under the framework of gradient boosting. In XGBoost, classification, and regression trees, CART, is created in sequential form. The basic idea is to continuously reduce the residual of the prior model in the gradient direction to get a new model.

The algorithm employs multiple regularization parameters, including LASSO (L1) and Ridge (L2), which help prevent overfitting and improve performance.

XGBoost has been successfully applied for binary classification problems such as microRNA/lncRNAdisease association predictions [38, 39] , prediction of hot spots in protein-DNA binding interfaces [40] , protein submitochondrial localization prediction [41] , etc. This study established a deep learning model in which

XGBoost was employed to perform the task of classification. The feature vectors obtained after convolution and pooling operations from the CNN were a dense, high-level representation of the original samples. We trained the XGBoost classifier with the training set features learned by CNN; the trained model could predict the correlation score for each unverified drug-virus pair in the dataset. The samples with scores above the threshold were considered as potential virus-drug associations, and they were released for future biological tests. We 

We conducted the fivefold CV to evaluate the predictive performance of DLEVDA in identifying new virusdrug relationships. In k-fold CV, the training set is separated into random subsets of uniform size. At each fold, the model was trained with k-1 subsets and validated with the remaining subset. The process was repeated k times until each subset was validated once, and the mean was taken as the end result. In the predicted results, known virus-drug relationships with correlation scores beyond the threshold were treated as true positives (TP), and lower than the threshold were treated as false negatives (FN) . Likewise, unknown relationships with correlation scores lower than the threshold were treated as true negatives (TN), and beyond the threshold were Fig. 3 . To diminish the deviations from randomly partitioned samples, we implemented fivefold CV twenty times, and the performances were averaged.

Additionally, we evaluated the model performance by implementing it on an independent test set. We generated the independent test set by randomly choosing 20 % samples from the training set such that it contains equal positive and negative samples. The remaining training set samples were partitioned into five random subsets of roughly equal size, which were used as the training and validation sets for the fivefold CV.

Next, the validated model is trained with the whole samples in the training set, excluding the independent test set. The trained model is used to predict the correlation score for the samples in the independent test set. The experimental results based on the independent test set are summarized in Tab. 2. 

We evaluated the predictive performance of DLEVDA by comparing it to related approaches. Existing researches for identifying repurposable anti-viral drugs against COVID-19 was rare as the COVID-19

researches were mainly focused on sequence data of viruses. We compared DLEVDA with other methods predicting virus-drug relationships such as the similarity constrained probabilistic matrix factorization, SCPMF [16] , and virus-drug association prediction based on random walk with restart, VDA-RWR [20] , using the same dataset we used. We further evaluated our model by comparing it to other association prediction approaches such as IMCMDA [46] , NCPMDA [47] , and SAEROF [48] . These three models achieved robust performances in their respective applications. IMCMDA was applied to identify new miRNA-disease associations based on the inductive matrix completion algorithm. NCPMDA identified novel diseases associated with miRNAs based on Network Consistency Projection. SAEROF was applied to predict novel drug-disease relationships utilizing sparse autoencoder and rotation forest. We compared DLEVDA with these models using the same dataset used in our study. The performance was evaluated based on the fivefold CV, and the results are depicted in Tab. 3.

From the table, it is evident that DLEVDA outperformed other methods with high robustness. 

To further assess the efficacy of DLEVDA, we compared the model performance with other state-of-the-art classifiers such as random forest (RF), support vector machine (SVM), and decision tree under fivefold CV. In order to assure the fairness of the experiment, we adopted the same feature construction and feature extraction 

To test the influence of various datasets in DLEVDA, we implemented it with another dataset that consists of 96 drug-virus associations between 78 drugs and 11 viruses. In this dataset, 12 viruses akin to SARS-CoV-2 were considered, and their genome sequence-based information was obtained from the NCBI database. Their pairwise similarities were computed using MAFFT version 7. The drugs associated with these viruses were acquired from Drugbank, NCBI, and PubMed databases, and their structural similarities were computed. We conducted respectively. The corresponding ROC and PR curves are plotted in Fig. 5 . The model performance is slightly low compared to the benchmark dataset used in this study as the number of training data is significantly less.

We downloaded this dataset from the supplementary material associated with the paper [20] . 

To further validate the predictive capability of DLEVDA, we conducted case studies on the top-predicted results. For this, we trained the model with all known drug-virus relationships and predicted correlation scores for all unknown drug-virus pairs in the dataset. The predicted correlation scores were sorted in descending order with the corresponding virus-drug relationships. Specifically, we ranked the top predicted drugs associated with the SARS-CoV-2, Tab. 4. Out of twelve top-predicted drugs, 9 of them could be validated by recent literature.

For example, ribavirin, the top-ranked drug against COVID-19, is an anti-viral drug used to treat Hepatitis C and some viral hemorrhagic fevers. It inhibits the replication of RNA viruses and has been applied for treating COVID-19 patients [49] [50] [51] . Nitazoxanide, the second top-predicted candidate drug, boosts the host's anti-viral response by upregulating the host interferon and impedes virus replication [52] . It has been proved that Nitazoxanide can prevent SARS-CoV-2 infections at a reduced micromolar concentration and has been recommended for clinical trials to treat COVID-19 [53] [54] [55] . The fourth-ranked drug favipiravir is one of the anti-viral agents considered in numerous clinical trials to combat COVID-19. Favipiravir is a purine nucleic acid analog with a broad spectrum of anti-RNA virus activities [56] [57] [58] [59] . In addition, among the top twelve predicted drugs against SARS-CoV-2, many are undergoing clinical trials [60, 61] . and other viral infectious diseases.

There are many factors attributed to the efficient performance of DLEVDA. Ensemble approaches yield excellent results by integrating the potency of multiple classifiers. CNN is a powerful feature extractor that automatically learns high-quality features from the raw input data. However, a large amount of training data is required by CNN to prevent overfitting [62] . The available training data for this research is limited. So, we employed XGBoost for the task of classification. XGBoost utilizes multicore CPU parallel computing to enhance performance. It combines software and hardware optimization strategies to produce more accurate results with lesser computing resources. The incorporation of a regularized model makes the classifier unique [37, 63] . However, we examine that XGBoost is still unclear for feature extraction. In addition, the potential of a single classifier may not be sufficient to meet the perfection required for many biological problems. In DLEVDA, the integration of CNN and XGBoost classifiers produced more accurate and robust results. We believe the performance of DLEVDA can be improved further as more drug-virus associations are discovered. Since similarity scores play a crucial part in predictive performance, it is required to further investigate the kinds of features bundled up for similarity computation.

The overall time complexity of DLEVDA can be expressed as ( ( * * �∑ ( * 2 =1 * * 2 ))�, ( * * * )), where the first and second components represent the time complexities of CNNbased feature learning and XGBoost-based classification, respectively, with training samples [66, 37] . In the first component, denotes the number of convolution layers, the number of epochs, the number of input channels, the spatial size of the kernel, the number of kernels, and the spatial size of the output feature map of the ℎ layer. In the second component, represents the total number of trees, the maximum depth of the tree, and the number of non-missing entries in the training data. From the equation, it can be inferred that the complexity of DLEVDA depends on the complexity ( * * �∑ ( * 2 =1 * * 2 ))� of CNNbased feature learning. The complexity of pooling and fully connected layers are not involved in this formulation. These layers may take 5-10% computational time.

In summary, this study proposed an efficacious deep learning ensemble model for rapid identification of 

The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health-The latest 2019 novel coronavirus outbreak in Wuhan

Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

SnapShot: Covid-19

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): an update

2019 novel coronavirus (COVID-19) outbreak: a review of the current literature

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges

Drug repurposing: progress, challenges and recommendations

A survey of current trends in computational drug repositioning

A review on drug repurposing applicable to COVID-19

The $2.6 billion pill-methodologic and policy considerations

An update on Drug Repurposing: Re-written saga of the drug's fate

Computational functional genomics-based approaches in analgesic drug discovery and repurposing

Bioinformatics resources facilitate understanding and harnessing clinical research of SARS-CoV-2

Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2

SAveRUNNER: A network-based algorithm for drug repurposing and its application to COVID-19

Drug repositioning based on similarity constrained probabilistic matrix factorization: COVID-19 as a case study

Repurposing novel therapeutic candidate drugs for coronavirus disease-19 based on protein-protein interaction network analysis

STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets

DGIdb 2.0: mining clinically relevant drug-gene interactions

Prioritizing anti-viral drugs against SARS-CoV-2 by integrating viral complete genome sequences and drug chemical structures

Random walk with restart on multiplex and heterogeneous biological networks

Predicting commercially available anti-viral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model

Self-attention based molecule representation for predicting drug-target interaction

Artificial intelligence approach fighting COVID-19 with repurposing drugs

DrugBank 4.0: shedding new light on drug mefigolism

A comparative study of SMILES-based compound similarity functions for drug-target interaction prediction

Open Babel: An open chemical toolbox

Why is Tanimoto index an appropriate choice for fingerprintbased similarity calculations?

Database resources of the national center for biotechnology information

MAFFT multiple sequence alignment software version 7: improvements in performance and usability

Backpropagation applied to handwritten zip code recognition

A learning-based framework for miRNA-disease association identification using neural networks

An efficient approach based on multi-sources information to predict circRNA-disease associations using deep convolutional neural network

An Ensemble Approach Based on Multi-Source Information to Predict Drug-MiRNA Associations via Convolutional Neural Networks

Rectified linear units improve restricted boltzmann machines

Dropout: a simple way to prevent neural networks from overfitting. The journal of machine learning research

Xgboost: A scalable tree boosting system

EGBMMDA: extreme gradient boosting machine for MiRNA-disease association prediction

LDNFSGB: prediction of long non-coding rna and disease association using network feature similarity and gradient boosting

Prediction of hot spots in protein-DNA binding interfaces based on supervised isometric feature mapping and extreme gradient boosting

SubMito-XGBoost: predicting protein submitochondrial localization by fusing multiple feature information and eXtreme gradient boosting

Receiver operating characteristic curve in diagnostic test assessment

Receiver operating characteristic (ROC) curve for medical researchers

The use of the Area under the ROC curve in the evaluation of machine learning algorithms

Area under the precision-recall curve: point estimates and confidence intervals

Predicting miRNA-disease association based on inductive matrix completion

Network consistency projection for human miRNA-disease associations inference

SAEROF: an ensemble approach for large-scale drugdisease association prediction by incorporating rotation forest and sparse autoencoder deep neural network

Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19

Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus

The FDA-approved oral drug nitazoxanide amplifies host anti-viral responses and inhibits Ebola virus

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Remdesivir (GS-5734) as a therapeutic option of 2019-nCOV main protease-in silico approach

Nitazoxanide against COVID-19 in three explorative scenarios

Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection

Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering

Favipiravir versus arbidol for COVID-19: a randomized clinical trial

Favipiravir and COVID-19: a simplified summary

Discovering drugs to treat coronavirus disease 2019 (COVID-19)

A review of potential suggested drugs for coronavirus disease (COVID-19) treatment

A comparison between shallow and deep architecture classifiers on small dataset

Application of the XGBoost machine learning method in PM2. 5 prediction: A case study of Shanghai

Convolutional neural networks at constrained time cost